This company has been marked as potentially delisted and may not be actively trading. OvaScience (OVAS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OVAS vs. WVE, OPK, ETNB, GERN, ELVN, NRIX, COLL, MLYS, RCUS, and ZYMEShould you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Wave Life Sciences (WVE), OPKO Health (OPK), 89bio (ETNB), Geron (GERN), Enliven Therapeutics (ELVN), Nurix Therapeutics (NRIX), Collegium Pharmaceutical (COLL), Mineralys Therapeutics (MLYS), Arcus Biosciences (RCUS), and Zymeworks (ZYME). These companies are all part of the "medical" sector. OvaScience vs. Wave Life Sciences OPKO Health 89bio Geron Enliven Therapeutics Nurix Therapeutics Collegium Pharmaceutical Mineralys Therapeutics Arcus Biosciences Zymeworks OvaScience (NASDAQ:OVAS) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings. Does the media refer more to OVAS or WVE? In the previous week, Wave Life Sciences had 16 more articles in the media than OvaScience. MarketBeat recorded 16 mentions for Wave Life Sciences and 0 mentions for OvaScience. Wave Life Sciences' average media sentiment score of 1.00 beat OvaScience's score of 0.00 indicating that Wave Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment OvaScience Neutral Wave Life Sciences Positive Do analysts rate OVAS or WVE? Wave Life Sciences has a consensus price target of $21.17, suggesting a potential upside of 166.58%. Given Wave Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Wave Life Sciences is more favorable than OvaScience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OvaScience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Wave Life Sciences 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of OVAS or WVE? 22.5% of OvaScience shares are owned by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are owned by institutional investors. 7.4% of OvaScience shares are owned by insiders. Comparatively, 29.1% of Wave Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community favor OVAS or WVE? Wave Life Sciences received 94 more outperform votes than OvaScience when rated by MarketBeat users. Likewise, 67.90% of users gave Wave Life Sciences an outperform vote while only 63.87% of users gave OvaScience an outperform vote. CompanyUnderperformOutperformOvaScienceOutperform Votes27463.87% Underperform Votes15536.13% Wave Life SciencesOutperform Votes36867.90% Underperform Votes17432.10% Which has better earnings and valuation, OVAS or WVE? OvaScience has higher earnings, but lower revenue than Wave Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOvaScience$290K878.45-$50.97MN/AN/AWave Life Sciences$108.30M11.25-$57.51M-$0.79-10.05 Which has more volatility & risk, OVAS or WVE? OvaScience has a beta of 3.11, suggesting that its share price is 211% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -0.93, suggesting that its share price is 193% less volatile than the S&P 500. Is OVAS or WVE more profitable? Wave Life Sciences has a net margin of -66.50% compared to OvaScience's net margin of -10,128.37%. OvaScience's return on equity of -47.06% beat Wave Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets OvaScience-10,128.37% -47.06% -42.39% Wave Life Sciences -66.50%-280.57%-52.90% SummaryWave Life Sciences beats OvaScience on 12 of the 17 factors compared between the two stocks. Get OvaScience News Delivered to You Automatically Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVAS vs. The Competition Export to ExcelMetricOvaSciencePharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$254.75M$6.69B$5.47B$7.92BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3222.5118.54Price / Sales878.45241.49397.62103.35Price / CashN/A65.8538.1834.62Price / Book3.956.486.734.25Net Income-$50.97M$143.41M$3.22B$248.18M OvaScience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVASOvaScienceN/A$7.11-3.1%N/A+111.5%$254.75M$290,000.000.00N/AWVEWave Life Sciences4.314 of 5 stars$6.56+7.2%$22.18+238.1%+56.6%$1.01B$108.30M-5.91240Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsOPKOPKO Health4.4752 of 5 stars$1.43+4.4%$2.75+92.3%+13.1%$960.32M$713.14M-7.534,200Earnings ReportAnalyst ForecastNews CoverageGap DownETNB89bio2.9783 of 5 stars$6.55+4.5%$27.25+316.0%-5.8%$956.20MN/A-2.2540Upcoming EarningsAnalyst UpgradeNews CoveragePositive NewsGERNGeron3.9984 of 5 stars$1.41+4.4%$5.75+307.8%-64.1%$898.05M$76.99M-4.4170Upcoming EarningsELVNEnliven Therapeutics2.2596 of 5 stars$17.97+10.8%$40.33+124.4%+8.9%$880.60MN/A-9.4650News CoverageNRIXNurix Therapeutics1.9305 of 5 stars$11.46+8.6%$30.44+165.7%-4.1%$873.67M$56.42M-3.97300Analyst ForecastPositive NewsGap DownCOLLCollegium Pharmaceutical4.0384 of 5 stars$26.89-0.1%$43.60+62.1%-26.9%$864.03M$631.45M11.59210Upcoming EarningsPositive NewsMLYSMineralys Therapeutics2.3833 of 5 stars$13.21-0.2%$33.00+149.8%+16.0%$857.01MN/A-3.6328Upcoming EarningsShort Interest ↑RCUSArcus Biosciences2.2787 of 5 stars$8.11+5.1%$30.25+273.2%-42.6%$852.14M$258M-2.57500Upcoming EarningsZYMEZymeworks2.7638 of 5 stars$12.16+3.5%$21.00+72.7%+51.6%$846.06M$76.30M-8.11460Upcoming EarningsAnalyst RevisionPositive News Related Companies and Tools Related Companies WVE Competitors OPK Competitors ETNB Competitors GERN Competitors ELVN Competitors NRIX Competitors COLL Competitors MLYS Competitors RCUS Competitors ZYME Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVAS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OvaScience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OvaScience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
